Last reviewed · How we verify

Lilly Bamlanivimab + Etesevimab

Erin McCreary · FDA-approved active Biologic

Bamlanivimab and etesevimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection.

Bamlanivimab and etesevimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection. Used for COVID-19 (mild to moderate disease in high-risk patients).

At a glance

Generic nameLilly Bamlanivimab + Etesevimab
SponsorErin McCreary
Drug classMonoclonal antibody combination (neutralizing antibodies)
TargetSARS-CoV-2 spike protein receptor-binding domain
ModalityBiologic
Therapeutic areaInfectious Disease / Virology
PhaseFDA-approved

Mechanism of action

This combination therapy consists of two non-competing monoclonal antibodies directed against distinct epitopes on the SARS-CoV-2 spike receptor-binding domain. By simultaneously targeting different regions of the spike protein, the antibodies work synergistically to neutralize viral particles and reduce viral load in infected individuals. The dual-antibody approach was designed to reduce the risk of viral escape and resistance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: